Clinical Trials
38 trialsNCT05739981 2026-06-02
MRD
Imunon
Phase 1/2 Recruiting
NCT06915025 2026-06-02
OVATION-3
Imunon
Phase 3 Recruiting
NCT07024784 2026-06-02
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT06890338 2026-05-29
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT03393884 2026-05-04
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04516447 2026-04-07
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT04498117 2026-04-01
FLORA-5
CanariaBio Inc.
Phase 3 Active not recruiting
NCT05605535 2026-04-01
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
CanariaBio Inc.
Phase 2 Active not recruiting
NCT07322094 2026-01-07
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL Biotherapeutics, LLC
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05456685 2025-10-28
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
Phase 2 Active not recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed
NCT03635489 2024-10-03
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT01279291 2024-04-26
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT04814875 2024-02-14
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
Phase 1/2 Terminated
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT03038100 2023-02-17
IMagyn050
Hoffmann-La Roche
Phase 3 Completed
NCT03657966 2021-04-21
DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer
Sotio Biotech Inc.
Phase 2 Completed
NCT03704467 2020-11-13
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
EMD Serono
Phase 1 Completed
NCT00391118 2020-10-19
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")
Eli Lilly and Company
Phase 2 Completed
NCT02658214 2020-08-20
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
AstraZeneca
Phase 1 Completed
NCT01478685 2019-11-12
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
Phase 1 Completed
NCT00407407 2019-10-18
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Celgene
Phase 1 Terminated
NCT01663857 2019-09-11
A Study LY2228820 for Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00434642 2017-08-09
OCEANS
Genentech, Inc.
Phase 3 Completed
NCT01493505 2017-02-23
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
Amgen
Phase 3 Terminated
NCT00382811 2016-07-18
OVATURE
MEI Pharma, Inc.
Phase 3 Completed
NCT01253681 2015-10-14
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
Amgen
Phase 1 Completed
NCT00421889 2015-07-28
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
Valerio Therapeutics
Phase 1/2 Completed
NCT00698451 2013-09-06
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00191646 2011-03-04
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Eli Lilly and Company
Phase 3 Completed
NCT00063401 2010-04-08
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Eli Lilly and Company
Phase 2 Completed